— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children
Most Popular
Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect
Johnson & Johnson's (NYSE: JNJ) business strategy for fiscal 2025 is focused on reducing the impact of patent expirations on its revenue. Anticipating sales to benefit from growth initiatives, including
What to expect when United Airlines (UAL) reports its Q2 2025 earnings results
Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) stayed green on Tuesday. The stock has gained 44% over the past three months. The airline company is scheduled to report its
Earnings Preview: Fastenal Company likely to report higher Q2 sales and profit
Fastenal Company (NASDAQ: FAST), a leading provider of industrial and construction supplies, is set to publish its second-quarter results next week. The company is among the hardest hit by the
Comments
Comments are closed.